<DOC>
	<DOCNO>NCT02036554</DOCNO>
	<brief_summary>To evaluate prevention effect combination therapy Everolimus low-dose Tacrolimus comparison standard-dose Tacrolimus therapy Mycophenolic acid New Onset Diabetes Mellitus transplantation renal allograft recipient</brief_summary>
	<brief_title>Evaluate Efficacy Study Combination Therapy Everolimus Low Dose Tacrolimus Renal Allograft Recipients</brief_title>
	<detailed_description>An open-label , randomize , multi-center , comparative parallel study evaluate prevention effect combination therapy Everolimus low-dose Tacrolimus comparison standard-dose Tacrolimus therapy Mycophenolic acid New Onset Diabetes Mellitus transplantation renal allograft recipient : PROTECT study</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>1 . Age ≥ 20 year old 2 . At least 3 month kidney transplantation 3 . Subject use Tacrolimus ± purine synthesis inhibitor + steroid without change within past 3 month ( except dosage ) 4 . MDRD eGFR ≥ 50 mL/min serum creatinine &lt; 2.0mg/dL within past 3 month 6months kidney transplantation 5 . Rate change serum creatinine &lt; +30 % within past 3 month 6months kidney transplantation ( serum creatinine decrease , without rate change inclusion possible . serum creatinine result normal , regardless rate change able register . ) 6 . Urine protein/creatinine ratio &lt; 1g/g Cr ( spot urine ) Subject applicable diagnostic criterion NODAT 7. baseline 6months kidney transplantation 8 . Subjects agree write informed consent 1 . Subjects receive combined nonrenal transplantation 2 . Subject receive retransplantation 3 . ABO blood group incompatible ( antiABO Antibody titer &lt; 1:128 inclusion possible . ) 4 . Sensitized patient transplantation Pretransplant peak PRA titer &gt; 50 % Pretransplant T cell cytotoxicity crossmatch ( + ) 5 . HLAidentical living relate donor 6 . Subject diabetes mellitus / NODAT transplantation 7 . Subject suffer acute rejection episode within past 3 month 6months kidney transplantation 8 . Subject hypersensitivity everolimus 9 . Subject continue nephrotoxic drug enrollment ( Aminoglycoside , amphotericin B , cisplatin ) 10 . Subject GI disorder might interfere ability absorb oral medication . ( eg , gastrectomy insufficiently treat diabetic gastroenteropathy ) 11 . Subjects active peptic ulcer 12 . HIV , HBsAg , HCV Ab test ( + ) 13 . Abnormal liver function test ( AST ALT total bilirubin &gt; upper normal limit x3 ) 14 . ANC &lt; 1.5*109/L WBC &lt; 2.5*109/L platelet &lt; 75*109/L 15 . Treatment investigational drug within 30 day precede first dose trial medication 16 . Women either pregnant , lactating , plan become pregnant next 12 month . 17 . Subjects history cancer ( except successfully treat ) , localize nonmelanocytic skin cancer , PTLD ( Posttransplant lymphoproliferative disorder ) 18 . Subjects clinically significant infection within past 4 week 6months kidney transplantation 19 . Subjects take major surgery within past 4 week 6months kidney transplantation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>